Core Insights - Innovent Biologics has announced updated results from a pivotal Phase 2 clinical trial of Dupert® (fulzerasib) for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, presented at the 2024 World Conference on Lung Cancer [1] - Fulzerasib has received approval from the NMPA in August 2024 for treating adult patients with advanced NSCLC harboring the KRAS G12C mutation who have received at least one systemic therapy [1][2] - The clinical trial showed a confirmed objective response rate (ORR) of 49.1% and a disease control rate (DCR) of 90.5%, with a median progression-free survival (PFS) of 9.7 months [1] Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing high-quality medicines for various diseases, including cancer and autoimmune disorders [3] - The company has launched 11 products and has multiple assets in various stages of clinical trials, including 3 new drug applications under regulatory review [3] - Innovent collaborates with over 30 global healthcare companies, enhancing its research and development capabilities [3] Product Details - Fulzerasib is a novel, orally active KRAS G12C inhibitor designed to target the GTP/GDP exchange, leading to tumor cell apoptosis and cell cycle arrest [2] - The KRAS G12C mutation is prevalent in various cancers, including 15-20% of lung cancers, making it a significant target for treatment [2] - The drug has received Breakthrough Therapy Designation from the CDE of China's NMPA for treating advanced NSCLC and colorectal cancer patients with KRAS G12C mutation [2]
Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation